Tuesday, April 28, 2015 10:17:57 AM
I continue to correct you regarding what I said about .25 which has to do with the warrants to be exercised.
When it comes to price there is no need set the bar on the downside to .25 (at last count I had 84 stocks worth ZERO in my portfolios).
Let me remind you of something:
_______________
Vtesse Inc. raises $25M Series A led by NEA
Biotech accelerator Cydan Development Inc. announced Wednesday $25 million in Series A funding to launch Vtesse Inc., which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children.
The series was led by New Enterprise Associates, along with Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.
The launch of Vtesse, which will be based in Gaithersburg, is the first such company to come out of Cambridge, Massachusetts-based Cydan Development, which is working to spin out additional companies with a focus on rare diseases with few viable treatments.
"We're very optimistic this could be an important therapeutic option for children," Vtesse CEO Ben Machielse told me.
The National Institute of Health has transferred to Vtesse exclusive worldwide rights to cyclodextrin, delta-tocopherol and derivatives of tocopherol, all of which have been under development at NIH for the treatment of lysosomal storage diseases.
Vtesse will use the funding to conduct a clinical program for VTS-270, a formulation of 2-hydroxypropyl-beta-cyclodextrin to treat a form of Niemann-Pick disease, a lyosomal storage disorder
_________________
The NIH has given its Imprimatur to VTESSE.
There is no question in my mind that Vtesse has leaped-frogged over CTDH.
This is now a David and Goliath story.
As a shareholder of the CTDH I would be happy to see CTDH take the lead and win... because I have no financial interest in VTESSE. Is it possible for CTDH to win this race? Sure it possible. Is it PROBABLE???? I think not.
Let's remember that last year CTDH over trebled their professional fees:
Professional fees (2014)---> 432,993
(2013)---> 142,860
while simultaneously achieving LOWER cyclodextrin sales.
This news looks to me like its about the hiring of more professionals to help CTDH stay in the race.
So now... we watch and wait.
Happy Trading
Recent CYTH News
- Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/16/2024 12:05:00 PM
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:46:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:45:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:44:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:43:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:42:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:41:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:40:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:44:54 PM
- Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office • Business Wire • 01/29/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:01:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:50:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:48:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:28:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:25:09 AM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:21 PM
- Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 • Business Wire • 12/18/2023 02:15:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 12/18/2023 11:02:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 11:01:44 AM
- Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 12/14/2023 09:01:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM